Atossa Stock Analysis

ATOS -  USA Stock  

USD 5.35  0.21  4.09%

The latest price spike of Atossa Therapeutics could raise concerns from retail investors as the firm it trading at a share price of 5.35 on 16,655,400 in volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in July. The stock standard deviation of daily returns for 90 days investing horizon is currently 8.36. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Atossa Therapeutics partners.
Please continue to Trending Equities.

Search Stock Analysis 

 
Refresh
The Atossa Therapeutics stock analysis report makes it easy to digest most publicly released information about Atossa Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Atossa stock analysis module also helps to analyze the Atossa Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Atossa Stock Analysis Notes

The company recorded a loss per share of 1.98. Atossa Therapeutics had not issued any dividends in recent years. The entity had 1:15 split on the 20th of April 2018. Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Atossa Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. For more info on Atossa Therapeutics please contact Steven Quay at 206 325 6068 or go to http://www.atossatherapeutics.com.

Atossa Therapeutics Quarterly Cost of Revenue

0.0Share

Atossa Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Atossa Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Atossa Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Atossa Therapeutics is way too risky over 90 days horizon
Atossa Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 1.76 K. Net Loss for the year was (22.33 M) with loss before overhead, payroll, taxes, and interest of (36.57 K).
Atossa Therapeutics currently holds about 39.55 M in cash with (11.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33.
Atossa Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from seekingalpha.com: Atossa Therapeutics to be included in the Russell 2000, 3000 indexes - Seeking Alpha

Atossa Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Atossa Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Atossa Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Atossa Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
18th of May 2021
Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
14th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
31st of March 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
23rd of March 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
22nd of March 2021
Termination of a Material Definitive Agreement
View
15th of January 2021
Unclassified Corporate Event
View
14th of January 2021
Unclassified Corporate Event
View
8th of January 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View

Atossa Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Atossa Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Atossa Therapeutics backward and forwards among themselves. Atossa Therapeutics' institutional investor refers to the entity that pools money to purchase Atossa Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Renaissance Technologies LlcCommon Shares3.3 MM
Vanguard Group IncCommon Shares3.2 M6.7 M
Group One Trading LpCall OptionsM4.3 M
Blackrock IncCommon Shares1.5 M3.2 M
Sabby Management LlcPut Options12.7 K2.7 M
Geode Capital Management LlcCommon Shares488.1 KM
Cvi Holdings LlcCommon Shares432.3 K912 K
Virtu Financial LlcCommon Shares271.9 K574 K
Sabby Management LlcCommon Shares242.2 K511 K
Note, although Atossa Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Atossa Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 558.21 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Atossa Therapeutics's market, we take the total number of its shares issued and multiply it by Atossa Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Atossa Profitablity

Atossa Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Atossa Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Atossa Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Atossa Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Atossa Therapeutics' profitability requires more research than a typical breakdown of Atossa Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(1.17) (1.26) 
Return on Average Equity(1.59) (1.71) 
Return on Invested Capital 7.40  7.99 
Return on Sales-8.1 K-8.3 K

Management Efficiency

The entity has return on total asset (ROA) of (31.85) % which means that it has lost $31.85 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (88.42) %, meaning that it created substantial loss on money invested by shareholders. Atossa Therapeutics management efficiency ratios could be used to measure how well atossa therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 06/19/2021, Return on Invested Capital is likely to grow to 7.99, while Return on Average Assets are likely to drop (1.26) . Atossa Therapeutics Total Assets are relatively stable at the moment as compared to the past year. Atossa Therapeutics reported last year Total Assets of 42.84 Million. As of 06/19/2021, Current Assets is likely to grow to about 46.1 M, while Return on Average Assets are likely to drop (1.26) .
Last ReportedProjected for 2021
Book Value per Share 2.40  2.46 
Enterprise Value over EBIT(3.45) (3.72) 
Enterprise Value over EBITDA(3.31) (3.57) 
Price to Book Value 2.50  2.58 
Tangible Assets Book Value per Share 3.79  3.89 
Enterprise Value58.8 M63.4 M
Tangible Asset Value42.8 M46.2 M

Technical Drivers

As of the 19th of June, Atossa Therapeutics shows the Risk Adjusted Performance of 0.1079, downside deviation of 7.68, and Mean Deviation of 5.76. Atossa Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for Atossa Therapeutics, which can be compared to its rivals. Please confirm Atossa Therapeutics coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Atossa Therapeutics is priced correctly, providing market reflects its regular price of 5.35 per share. Given that Atossa Therapeutics has jensen alpha of 1.25, we suggest you to validate Atossa Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Atossa Therapeutics Price Movement Analysis

The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Triangular Moving Average shows Atossa Therapeutics double smoothed mean price over a specified number of previous prices (i.e., averaged twice). View also all equity analysis or get more info about triangular moving average overlap studies indicator.

Atossa Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atossa Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atossa Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atossa Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Atossa Therapeutics Predictive Daily Indicators

Atossa Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Atossa Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Atossa Therapeutics Forecast Models

Atossa Therapeutics time-series forecasting models is one of many Atossa Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Atossa Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Atossa Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Atossa Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Atossa shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Atossa Therapeutics. By using and applying Atossa Stock analysis, traders can create a robust methodology for identifying Atossa entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(14.67) (15.83) 
Gross Margin(66.89) (68.65) 
Profit Margin(15.34) (16.55) 
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Atossa Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people.

Current Atossa Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Atossa analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Atossa analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
6.0Buy2Odds
Atossa Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Atossa analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Atossa stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Atossa Therapeutics, talking to its executives and customers, or listening to Atossa conference calls.
Atossa Analyst Advice Details

Atossa Stock Analysis Indicators

Atossa Therapeutics stock analysis indicators help investors evaluate how Atossa Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Atossa Therapeutics shares will generate the highest return on investment. By understating and applying Atossa Therapeutics stock analysis, traders can identify Atossa Therapeutics position entry and exit signals to maximize returns.
Quick Ratio2.56
Fifty Two Week Low0.8100
Shares Short Prior Month6.59M
Average Daily Volume Last 10 Day40.16M
Average Daily Volume In Three Month13.04M
Shares Percent Shares Out8.68%
Short Percent Of Float8.68%
Forward Price Earnings-30.80
Float Shares120.8M
Fifty Two Week High6.8200
Enterprise Value To Ebitda-17.91
Fifty Day Average3.2291
Two Hundred Day Average2.3336
Please continue to Trending Equities. Note that the Atossa Therapeutics information on this page should be used as a complementary analysis to other Atossa Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Atossa Therapeutics Stock analysis

When running Atossa Therapeutics price analysis, check to measure Atossa Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Therapeutics is operating at the current time. Most of Atossa Therapeutics' value examination focuses on studying past and present price action to predict the probability of Atossa Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atossa Therapeutics' price. Additionally, you may evaluate how the addition of Atossa Therapeutics to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
The market value of Atossa Therapeutics is measured differently than its book value, which is the value of Atossa that is recorded on the company's balance sheet. Investors also form their own opinion of Atossa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atossa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atossa Therapeutics' market value can be influenced by many factors that don't directly affect Atossa Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atossa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Atossa Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atossa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.